Ahmed A, Williams DJ, Cheed V, et al. - Researchers examined how pravastatin affects plasma fms-like tyrosine kinase-1 (sFlt-1) levels during preeclampsia. They conducted blinded (clinician and participant), proof of principle, placebo-controlled trial at 15 UK maternity units. Using a minimization algorithm, they assigned 62 women with early-onset preeclampsia (24⁺⁰ - 31⁺⁶ weeks' gestation) to receive pravastatin 40mg daily (n = 30) or matched placebo (n = 32), from randomization to childbirth. Women who received pravastatin vs those who received placebo had a similar length of pregnancy following randomization. Findings yielded no evidence indicating the lowering of maternal plasma sFlt-1 levels in relation to the receipt of pravastatin once early-onset preeclampsia had developed. No adverse perinatal effects of pravastatin were observed.